Project Aim(s): PD-MitoQUANT is an Innovative Medicines Initiative (IMI)Innovative Medicines Initiative (IMI) (www.imi.europa.eu) project that brings together academic experts, small and medium enterprises (SMEs), pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA)European Federation of Pharmaceutical Industries and Associations (EFPIA) (www.efpia.eu) and patient advocacy organisation Parkinson’s UKParkinson’s UK (www.parkinsons.org.uk).

The project aims to:

1) Improve our understanding of mitochondrial dysfunction in Parkinson’s  disease.

2) Identify and validate molecular drivers and mechanisms in Parkinson’s disease.

3) Discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future, and

4) Initiate a European research platform of excellence in PD that will continue beyond the project, providing long-term and sustainable progress in the understanding of mitochondrial dysfunction in PD, towards clinical application.